To assess long-term safety and immunogenicity of collagenase clostridium histolyticum (collagenase) and characterize curvature deformity over time in patients previously treated with collagenase for Peyronie's disease (PD).
INTRODUCTION AND OBJECTIVES:
To assess long-term safety and immunogenicity of collagenase clostridium histolyticum (collagenase) and characterize curvature deformity over time in patients previously treated with collagenase for Peyronie's disease (PD).
METHODS: Follow-up study of patients who received collagenase in 2 large, 12-month, double-blind, placebo-controlled clinical trials (IMPRESS I/II) or one of two 9-month, open-label studies. Eligible patients were followed yearly for up to 5 years after initial collagenase injection. Adverse events (AEs) were collected throughout the study. Penile curvature characterization and PDQ were compared to Reference data (measurements obtained at last visit in 1 of the prior studies).
RESULTS: Of 280 patients enrolled, 204 completed the study. From baseline to last visit (Reference) of the prior studies (n[247), mean AE SD penile curvature decreased from 51.8 AE 15.0 degrees to 31.0 AE 16.1 degrees (improvement of 20.9 AE 16.2 degrees; 39.5%). At Year 5 follow-up (n[180), there was an additional 9.1% improvement in mean penile curvature versus Reference data (4.3 degrees; 95% CI, 2.3-6.2 degrees; P[0.02). Twenty-nine patients were excluded from the 5-year analysis of curvature characterization: 9 who received additional collagenase injection(s), 2 with penile implants, and 18 with prior surgery for PD. There was a significant mean reduction of PDQ bother score at Year 5 from Reference (n[123; mean reduction (AE SD), 0.9 AE 2.5 , P[0.0003). Additional improvements were seen in PDQ pain and psychologic and physical symptoms domains at Year 5 visit versus Reference scores. There was a mean increase of 0.5 AE 1.29 cm in penile length from Baseline to Reference in prior studies, and the length was maintained to Year 5. AEs were reported in 17.5% (49/280) of patients; none were considered treatment related. No long-term safety issues were identified. There was a trend toward a decrease in the number of anti-AUX-I and anti-AUX-II seropositive patients at Years 4 and 5 (100% in Year 2 to w98% at Year 4 and 90.9% at Year 5). Mean log antibody titer levels for anti-AUX-I decreased from 4.9 at maximum in previous studies to 3.8, 3.8, and 3.7, in Years 3, 4, and 5, respectively; anti-AUX-II decreased from 4.5 to 3.6, 3.5, and 3.4 in Years 3, 4, and 5, respectively.
CONCLUSIONS: This 5-year study did not reveal additional long-term safety or tolerability signals. Most patients continued to have improvement in PD curvature and bother through 5 years of follow-up without additional treatment.
Source of Funding: Endo Pharmaceuticals Inc.
MP65-07 ADHERENCE TO COLLAGENASE CLOSTRIDIUM HISTOLYTICUM LABEL RECOMMENDATIONS AND PROVIDER SATISFACTION: A SURVEY OF INTERNATIONAL SOCIETY FOR SEXUAL MEDICINE MEMBERS
Alex Galante*, Gainesville, FL; Thomas Masterson, Mohit Butaney, Miami, FL; Alexander Pastuszak, Salt Lake City, UT; Hossein Sadeghi-Nejad, Newark, NJ; Ranjith Ramasamy, Miami, FL INTRODUCTION AND OBJECTIVES: Collagenase clostridium histolyticum (CCH, Xiaflex) is the only FDA-approved medication for treatment of Peyronie's disease since 2013. It is unclear how practitioners actually use CCH in their own practices. The objectives of the study were: 1) to identify variability in practice patterns for CCH among practitioners, 2) to assess adherence to the package insert instructions and 3) to evaluate whether provider satisfaction was associated with adherence to instructions.
METHODS: A 30-question online survey was distributed to 1,270 members of the International Society for Sexual Medicine (ISSM) from the EU, USA, Canada and Australia. Of the 30 questions, 10 survey questions had only one response consistent with the CCH package insert recommendations. An adherence score was calculated for each survey participant depending on how many of these questions were answered correctly. The average adherence scores of various groups were compared using a t-test. A chi-squared test was used to determine association between categorical variables.
RESULTS: Of 202 total responses, 132 practitioners reported using CCH out of 1,270 ISSM members from countries where CCH is available (10.4% response rate). Practitioners from the USA had significantly better adherence scores than those outside the USA (average 7.7 vs 5.9, p<0.001). Practitioners from outside the USA were more likely to be satisfied with CCH (p[0.006), and more experienced users (>20 uses) were more likely to be satisfied than less experienced users (<10 uses) (p[0.046). Satisfied users of CCH did not have significantly different adherence scores than non-satisfied users.
CONCLUSIONS: There appears to be wide variability in CCH practice patterns among the international urology community. Even though 67% of practitioners believed they followed the package insert guidelines, only 11% adhered to all the recommendations evaluated by the survey. More experienced users and practitioners outside the USA tended to be more satisfied with the product. Treatment adherence to package insert guidelines dose not appear to be associated with provider satisfaction. (PD) . To date, however, there are no published reports specifically examining outcomes of treatment in patients with PD and significant indentation or hourglass deformity. We sought to assess outcomes in patients receiving ILI CCH for these specific deformities.
METHODS: We conducted a retrospective review of 13 patients with PD and significant indentation or hourglass deformity who began ILI CCH between November 2016 and June 2018. A penile duplex Doppler ultrasound (PDDU) was performed prior to initiation of therapy in all patients. Degree of curvature was measured at the time of PDDU, after the second cycle, and 4-6 weeks after completion of the fourth cycle. Patients were called after completing treatment and asked whether or not they were satisfied with their injections and if they would pursue this treatment again. Patients answered the symptom bother
